Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Masahiro Tsuboi et al.|New England Journal of Medicine|2020Cited by 1.7k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Masahiro Fukuoka, Tony Mok, Da-Tong Chu et al.|Journal of Clinical Oncology|2011Cited by 1.6k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLCMasahiro Tsuboi, Yi‐Long Wu, Thomas John et al.|New England Journal of Medicine|2023Cited by 605
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST StudyMatthew J. Ellis, J.F.R. Robertson, Antonio Llombart‐Cussac et al.|Journal of Clinical Oncology|2015Cited by 239